2004-2005 年配方(疫苗），NR-1_Vaccinia virus

NR-10477?? Fluzone? Influenza Virus Vaccine, 2004-2005 Formula(Vaccines)|Influenza A & B viruses|Fluzone? Influenza Virus Vaccine, 2004-2005 Formula|2°C to 8°C|NIAID/NIHAcknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Fluzone? Influenza Virus Vaccine, 2004-2005 Formula, NR-10477."|Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment.NR-10477 is a split-virus vaccine prepared from influenza viruses A/New Caledonia/20/1999 (H1N1), A/Wyoming/3/2003 (H3N2) [an A/Fujian/411/2002 (H3N2)-like strain] and B/Jiangsu/10/2003 (a B/Shanghai/361/2002-like strain) that were predicted to circulate in the United States during the 2004 to 2005 influenza season.The hemagglutinin content was standardized according to U.S. Public Health Service requirements. Each 0.25 mL syringe contains the recommended ratio of 7.5 ?g each of the hemagglutinin antigens from influenza viruses A/New Caledonia/20/1999 (H1N1), A/Wyoming/3/2003 (H3N2) and B/Jiangsu/10/2003.Please note that this vaccine preparation is being released for research use only and not for human use. Vaccines produced for the 2004-2005 season are now past their expiration dates.Each syringe contains 0.25 mL of split-virus vaccine in phosphate-buffered saline containing 0.05% gelatin and a trace amount of thimerosal (≤ 0.5 ?g mercury).

NR-10476?? Fluzone? Influenza Virus Vaccine, 2004-2005 Formula(Vaccines)|Influenza A & B viruses|Fluzone? Influenza Virus Vaccine, 2004-2005 Formula|2°C to 8°C|NIAID/NIHAcknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Fluzone^? Influenza Virus Vaccine, 2004-2005 Formula, NR-10476."|Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment.NR-10476 is a split-virus vaccine prepared from influenza viruses A/New Caledonia/20/1999 (H1N1), A/Wyoming/3/2003 (H3N2) [an A/Fujian/411/2002 (H3N2)-like strain] and B/Jiangsu/10/2003 (a B/Shanghai/361/2002-like strain) that were predicted to circulate in the United States during the 2004 to 2005 influenza season.The hemagglutinin content was standardized according to U.S. Public Health Service requirements. Each 0.25 mL syringe contains the recommended ratio of 7.5 ?g each of the hemagglutinin antigens from influenza viruses A/New Caledonia/20/1999 (H1N1), A/Wyoming/3/2003 (H3N2) and B/Jiangsu/10/2003.Please note that this vaccine preparation is being released for research use only and not for human use. Vaccines produced for the 2004-2005 season are now past their expiration dates.Each syringe contains 0.25 mL of split-virus vaccine in phosphate-buffered saline containing 0.05% gelatin and a trace amount of thimerosal (≤ 0.5 ?g mercury).